Quick answer
The Glow Stack is a co-lyophilized research blend of GHK-Cu (50 mg), BPC-157 (10 mg) and TB-500 (10 mg), 70 mg in total, supplied as a lyophilized powder in a sealed glass vial for laboratory research use only. GHK-Cu is a tripeptide-copper complex, BPC-157 is a 15-residue peptide and TB-500 is a name used for thymosin beta-4-derived peptides, commonly the 7-residue fragment LKKTETQ. This sheet collects identities, molar amounts, key primary papers and a glossary so that a reader can interpret the blend's documentation and the literature on each part. For laboratory research use only; not for human consumption.
Most pages about the Glow Stack lead with claims. This one is a reference sheet: what is in the vial, how much of each component in mass and in moles, which primary papers describe each one, and what the specialized terms on a certificate mean. It is a companion to the site's GLOW peptide blend overview, which covers reconstitution and storage in more depth, and to the product page, from which the composition facts here are taken. Nothing below is guidance for people; the studies cited used cells and animals.
Composition at a glance
| Item | Value | Source |
|---|---|---|
| Total mass | 70 mg per vial (50 / 10 / 10) | Product page |
| Components | GHK-Cu, BPC-157, TB-500 | Product page |
| Mass ratio | 5 : 1 : 1 | Calculated from the stated masses |
| Purity | ≥98% measured by HPLC | Product page |
| Form | Lyophilized powder in a sealed clear glass research vial | Product page |
| Storage | 2–8 °C; −20 °C for long-term; protect from heat, moisture and light | Product page |
| Identity and sequence | Reported on the certificate of analysis, where published | Product page |
| Intended use | Laboratory research only | Product page |
The lot-specific certificate is available on the COA page, and the testing approach is described in how to read a COA.
Component reference
| Property | GHK-Cu | BPC-157 | TB-500 |
|---|---|---|---|
| What it is | Copper(II) complex of Gly-His-Lys | Synthetic pentadecapeptide, partial sequence of a protein described from gastric juice | Name for thymosin beta-4-derived peptides; commonly the 7-residue fragment LKKTETQ |
| Residues | 3 | 15 | 7 for the fragment; 43 for full-length thymosin beta-4 |
| Approx. molecular weight | about 340 (peptide); about 404 (complex) | about 1,419.5 | about 889 for the acetylated fragment |
| Label mass | 50 mg | 10 mg | 10 mg |
| Approx. moles, assuming 100% content | about 124 µmol | about 7.0 µmol | about 11.2 µmol |
| Visible indicator | Blue in solution | Colorless | Colorless |
| Representative primary papers | Maquart 1988; Siméon 2000; Canapp 2003 | Chang 2011; Hsieh 2017 | Malinda 1999; Philp 2003; Goldstein 2005 |
Two notes on that table. The molecular weights are standard values and should be replaced with the certificate's figures if they differ. And the moles are upper bounds because they assume the label mass is all peptide; counter-ions and water lower net content. The practical consequence is that the blend is overwhelmingly GHK-Cu by mass and still more by moles, roughly 124 µmol against 7.0 and 11.2 µmol.
What each component's papers actually studied
GHK-Cu. A tripeptide reported in human serum in 1973 (Pickart and Thaler, 1973) that binds Cu(II) tightly, with a conditional dissociation constant near 7 × 10−14 M at pH 7.4 (Trapaidze and colleagues, 2012) and a three-nitrogen coordination in solution (Hureau and colleagues, 2011). In fibroblast cultures it stimulated collagen synthesis between about 10−12 and 10−9 M (Maquart and colleagues, 1988) and affected MMP and TIMP secretion (Siméon and colleagues, 2000).
BPC-157. In tendon explants it accelerated outgrowth and increased migration of tendon fibroblasts with FAK and paxillin phosphorylation (Chang and colleagues, 2011). In other work it increased vessel density in the chorioallantoic membrane and in endothelial tube formation and raised VEGFR2 expression (Hsieh and colleagues, 2017).
TB-500 and thymosin beta-4. Full-length thymosin beta-4 increased re-epithelialization in a rat wound model and stimulated keratinocyte migration (Malinda and colleagues, 1999), and the LKKTETQ actin-binding domain promoted repair in aged mice comparably to the parent molecule (Philp and colleagues, 2003). A review describes thymosin beta-4 as the major actin-sequestering molecule in eukaryotic cells (Goldstein and colleagues, 2005).
Glossary for reading blend documentation
| Term | Meaning in this context |
|---|---|
| Co-lyophilized | Freeze-dried together from one solution, so a single reconstitution gives all three peptides |
| Cake | The porous solid left after freeze-drying; pale blue here because of copper |
| HPLC purity | Share of the chromatographic signal belonging to the main peak; not net peptide content |
| Net peptide content | Fraction of the vial's mass that is peptide, after counter-ions and water |
| Conditional dissociation constant | A binding constant measured under stated pH and competing ligands, not a universal value |
| Chelator | A molecule that binds metal ions, such as EDTA, which can strip copper from the complex |
| Single-agent arm | An experimental group receiving only one component, needed to interpret a blend |
| Vehicle control | A group receiving diluent only |
| Lot or batch | A production unit with its own certificate |
| Mass spectrometry confirmation | Measurement of molecular mass to confirm identity |
The same terms recur across the site's guides. Understanding HPLC purity and HPLC vs mass spectrometry expand on the analytical ones.
Worked arithmetic for planning
Everything quantitative about the blend follows from three formulas: concentration (mg/mL) = component mass (mg) ÷ diluent volume (mL); molarity (mol/L) = concentration (g/L) ÷ molecular weight (g/mol); and C1V1 = C2V2 for dilutions. The table applies them to three diluent volumes, assuming a vial that can hold the volume and 100% peptide content.
| Diluent volume | GHK-Cu (mg/mL) | BPC-157 (mg/mL) | TB-500 (mg/mL) | GHK-Cu molarity | BPC-157 molarity | TB-500 molarity |
|---|---|---|---|---|---|---|
| 2 mL | 25 | 5 | 5 | about 62 mM | about 3.5 mM | about 5.6 mM |
| 4 mL | 12.5 | 2.5 | 2.5 | about 31 mM | about 1.8 mM | about 2.8 mM |
| 5 mL | 10 | 2 | 2 | about 25 mM | about 1.4 mM | about 2.2 mM |
Because the components differ in mass and in molecular weight, a molar series of one component cannot be built by simply diluting the blend; a one-to-one molar comparison between, for example, GHK-Cu and BPC-157 in the same well would need separate vials. This is a main reason experienced groups pair the blend with single-component stocks. The reconstitution calculator returns any other volume, and the steps for mixing are in how to reconstitute a lyophilized peptide.
Questions to ask before applying a paper to the blend
- Which molecule was tested? Full-length thymosin beta-4 and the 7-residue fragment are different molecules, and the blend's TB-500 identity comes from the certificate.
- Which species and tissue? A tendon fibroblast result is not a skin keratinocyte result.
- Which concentration? Compare the paper's working range to what a diluted blend would deliver, remembering that the three components arrive together at fixed ratios.
- Which control isolated the effect? Copper-salt and free-peptide arms were important in the GHK-Cu work (Siméon and colleagues, 2000), and a blend study needs the equivalent.
- Was the result replicated? Check whether independent groups reported the same endpoint, and say so when the answer is no.
These questions turn a literature review into a study design. A reader who answers them for each cited paper will usually find that the blend can be placed in a larger design, as one arm among several, but cannot by itself answer a question about any single component. It will also show which questions the literature simply has not asked yet, such as how the three peptides behave together in one culture medium, and those gaps are where an original experiment adds the most information. Writing those gaps down at the planning stage is a useful habit in itself.
Is there research on the three together?
No peer-reviewed study in the sources reviewed tested the three-peptide blend as one test article. Each component has its own literature in different models, so statements about combined effects are hypotheses. This is not a weakness of the product format; it simply defines what the blend is for, namely laboratories that want to study the open question with proper single-agent controls. The reasoning is developed in the evidence audit of skin and tissue-repair research and in Glow Stack vs individual peptides.
Blend or separate vials
| Consideration | Blend | Separate vials |
|---|---|---|
| Ratio | Fixed at 5 : 1 : 1 | Free to vary |
| Single-agent controls | Not possible from the blend alone | Straightforward |
| Reconstitution steps | One | Three |
| Calculations | One volume, three concentrations | Three independent calculations |
| Best fit | Fixed-ratio combination experiments | Concentration–response work on each peptide |
A rigorous combination study generally uses both formats. The individual vials are on the site as GHK-Cu, BPC-157 and TB-500, and the related four-component blend is described in the KLOW stack overview. Concentrations for any diluent volume come from component mass divided by volume, which the calculator returns.
Related reading
- GLOW peptide blend overview
- Glow vs KLOW vs Wolverine stack
- Peptide blends and research stacks
- Research peptide stacks in 2026
- Where to buy the Glow Stack for research
- Research peptide catalog
Frequently asked questions
What is in the Glow Stack?
A co-lyophilized blend of GHK-Cu (50 mg), BPC-157 (10 mg) and TB-500 (10 mg), 70 mg total, per the product page.
What is the mass ratio of the Glow Stack components?
5 : 1 : 1 by mass, which is far more skewed toward GHK-Cu on a molar basis because of its low molecular weight.
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 has 43 residues, and TB-500 is a name used for derived peptides, commonly the 7-residue LKKTETQ fragment. Check the certificate.
Why is the Glow Stack solution blue?
The copper(II) complex of GHK gives it the color. BPC-157 and TB-500 are colorless, so color does not confirm them.
Which papers should I read for each component?
Maquart 1988, Siméon 2000 and Canapp 2003 for GHK-Cu; Chang 2011 and Hsieh 2017 for BPC-157; Malinda 1999 and Philp 2003 for thymosin beta-4 and its fragment.
Has the blend itself been studied?
Not in any peer-reviewed study found in the sources reviewed. Combination effects are hypotheses to be tested with single-agent controls.
Where is the lot certificate?
On the site's COA page, which lists certificates where they have been published.
Related reading: Glow Stack Storage: Copper Compatibility Troubleshooting, Glow Stack Synergy: How to Test It in the Lab, Glow Stack vs Wolverine Stack: What GHK-Cu Changes.
References
- Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver cells. Nat New Biol. 1973;243(124):85-87. PMID:4349963
- Trapaidze A, Hureau C, Bal W, Winterhalter M, Faller P. Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine. J Biol Inorg Chem. 2012;17(1):37-47. doi:10.1007/s00775-011-0824-5
- Hureau C, Eury H, Guillot R, Bijani C, Sayen S, Solari PL, et al.. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(36):10151-60. doi:10.1002/chem.201100751
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. doi:10.1016/0014-5793(88)80509-x
- Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65. doi:10.1016/s0024-3205(00)00803-1
- Canapp SO Jr, Farese JP, Schultz GS, Gowda S, Ishak AM, Swaim SF, et al.. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32(6):515-23. doi:10.1111/j.1532-950x.2003.00515.x
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. doi:10.1152/japplphysiol.00945.2010
- Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, et al.. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y
- Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, et al.. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. doi:10.1046/j.1523-1747.1999.00708.x
- Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. doi:10.1046/j.1524-475x.2003.11105.x
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-9. doi:10.1016/j.molmed.2005.07.004
